NCT00744679 - A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

Multiple Sclerosis

Interventions

DRUG

Natalizumab

Participants continue to receive regularly-scheduled doses of Tysabri (300 mg infusion every 28±7 days) through the Tysabri Outreach: United Commitment to Health Prescribing Program (TOUCH) throughout the screening and assessment periods. Participants must continue to be dosed every 28±7 days in order to maintain steady-state pharmacokinetics.

Trial Locations (1)

Unknown

Research Site, Latham